ArticleThe Journal of experimental medicine2015
BAFF activation of the ERK5 MAP kinase pathway regulates B cell survival.
Article in The Journal of experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Targeting B-Cell-Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia.American journal of hematology · 2026Review
- BAFF and APRIL Receptors in B Cell Immunity and Autoimmunity.Immunological reviews · 2026Review
- Machine Learning and Experimental Validation of m6A RNA Methylation Related Signatures for Risk Prediction, Diagnostic Biomarkers, and Immune Subtypes in Chronic Kidney Disease.Journal of inflammation research · 2026Article
- Posttranscriptional control of the B cell receptor by HuR is essential for innate B cell maintenance and function.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL.Signal transduction and targeted therapy · 2025Article
- Expression of USP25 associates with fibrosis, inflammation and metabolism changes in IgG4-related disease.Nature communications · 2024Article
- [Research advances on B-cell activating factor and its targeted agents in inflammatory bowel disease].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Review
- Supplying the trip to antibody production-nutrients, signaling, and the programming of cellular metabolism in the mature B lineage.Cellular & molecular immunology · 2022Review
- FCRL1 Regulates B Cell Receptor-Induced ERK Activation through GRB2.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Review
- Sphere-induced reprogramming of RPE cells into dual-potential RPE stem-like cells.EBioMedicine · 2020Article
- Phf6-null hematopoietic stem cells have enhanced self-renewal capacity and oncogenic potentials.Blood advances · 2019Article
- Oncogenic and tumor suppressive roles of special AT-rich sequence-binding protein.Journal of carcinogenesis · 2018Review
- Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance.Frontiers in immunology · 2018Article
- O-GlcNAcylation is required for B cell homeostasis and antibody responses.Nature communications · 2017Article
- Efficient generation of antigen-specific CTLs by the BAFF-activated human B Lymphocytes as APCs: a novel approach for immunotherapy.Oncotarget · 2016Article
- Absence of ERK5/MAPK7 delays tumorigenesis in Atm-/- mice.Oncotarget · 2016Article
- SATB2 suppresses gastric cancer cell proliferation and migration.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Erk5 contributes to maintaining the balance of cellular nucleotide levels and erythropoiesis.Cell cycle (Georgetown, Tex.) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
B cell activating factor (BAFF) stimulation of the BAFF receptor (BAFF-R) is essential for the homeostatic survival of mature B cells. Earlier in vitro experiments with inhibitors that block MEK 1 and 2 suggested that activation of ERK 1 and 2 MAP kinases is required for BAFF-R to promote B cell survival. However, these inhibitors are now known to also inhibit MEK5, which activates the related MAP kinase ERK5. In the present study, we demonstrated that BAFF-induced B cell survival was actually independent of ERK1/2 activation but required ERK5 activation. Consistent with this, we showed that conditional deletion of ERK5 in B cells led to a pronounced global reduction in mature B2 B cell numbers, which correlated with impaired survival of ERK5-deficient B cells after BAFF stimulation. ERK5 was required for optimal BAFF up-regulation of Mcl1 and Bcl2a1, which are prosurvival members of the Bcl-2 family. However, ERK5 deficiency did not alter BAFF activation of the PI3-kinase-Akt or NF-κB signaling pathways, which are also important for BAFF to promote mature B cell survival. Our study reveals a critical role for the MEK5-ERK5 MAP kinase signaling pathway in BAFF-induced mature B cell survival and homeostatic maintenance of B2 cell numbers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.